Parmax Pharma Ltd Q1 FY2022-23 loss at Rs. 1.31 crore

Parmax Pharma Ltd has reported Standalone financial results for the period ended June 30, 2022.

Financial Results (Q1 FY2023) - QoQ Comparison

The company has reported total income of Rs. 1.5637 crores during the period ended June 30, 2022 as compared to Rs. 7.1047 crores during the period ended March 31, 2022.

The company has posted net profit / (loss) of Rs. -1.3180 crores for the period ended June 30, 2022 as against net profit / (loss) of Rs. -0.0459 crores for the period ended March 31, 2022.

The company has reported EPS of Rs. -3.52 for the period ended June 30, 2022 as compared to Rs. -0.12 for the period ended March 31, 2022.

Financials	Q1 FY2023	Q4 FY2022	% Change
Total Income	₹ 1.5637 crs	₹7.1047 crs	-77.99%
Net Profit	₹-1.3180 crs	₹-0.0459 crs	2,771.46%
EPS	₹-3.52	₹-0.12	2,833.33%

Financial Results (Q1 FY2023) - YoY Comparison

The company has reported total income of Rs. 1.5637 crores during the period ended June 30, 2022 as compared to Rs.1.7505 crores during the period ended June 30, 2021.

The company has posted net profit / (loss) of Rs.-1.3180 crores for the period ended June 30, 2022 as against net profit / (loss) of Rs.-0.4350 crores for the period ended June 30, 2021.

The company has reported EPS of Rs.-3.52 for the period ended June 30, 2022 as compared to Rs.-1.16 for the period ended June 30, 2021.

Financials	Q1 FY2023	Q1 FY2022	% Change
Total Income	₹ 1.5637 crs	₹1.7505 crs	-10.67%
Net Profit	₹-1.3180 crs	₹-0.4350 crs	202.99%
EPS	₹-3.52	₹-1.16	203.45%

Shares of Parmax Pharma Ltd was last trading in BSE at Rs. 29.20 as compared to the previous close of Rs. 31.85. The total number of shares traded during the day was 2873 in over 39 trades.

The stock hit an intraday high of Rs. 32.50 and intraday low of 28.70. The net turnover during the day was Rs. 84065.00.

Source : Equity Bulls

Keywords

ParmaxPharma Q1FY23 ResultUpdate